SRI-20920

Class: Dihydrofolate reductase inhibitor

Details of activity:	Mycobacterium avium dihydrofolate reductase inhibitors; most active compound in series against Mycobacterium avium
Description:	Barrow EW, Suling WJ, Seitz, LE, etc. Screening of new selective inhibitors for Mycobacterium avium DHFR. Poster F-734 44th-ICAAC 2004;206.
Institute where first reported:	Oklahoma State Univ., Coll of Vet. Med., US; Southern Res. Inst., USA
Year first mentioned:	2004
Highest developmental phase:	Preclinical
Development status:	Inactive
Reason Dropped:	These were presented in early stages of the work. They suggest other compounds in the series in development which better solubility and selectivity. It is likely, these were superseded.

Chemical structure(s):
Canonical SMILES:	CCCOC1=CC=C(C=C1NCC2=C(C)C3=C(N)N=C(N)N=C3N=C2)OCC
Isomeric SMILES:	CCCOC1=C(C=C(C=C1)OCC)NCC2=CN=C3C(=C2C)C(=NC(=N3)N)N
InChI:	InChI=1S/C20H26N6O2/c1-4-8-28-16-7-6-14(27-5-2)9-15(16)23-10-13-11-24-19-17(12(13)3)18(21)25-20(22)26-19/h6-7,9,11,23H,4-5,8,10H2,1-3H3,(H4,21,22,24,25,26)
InChI Key:	SZAZJRVSIHGLCG-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/15954345

External links:
Guide to Pharmacology:	SRI-20920
Citation:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1280141/